Anzeige
Mehr »
Samstag, 08.08.2026 - Börsentäglich über 12.000 News
Schwere Seltene Erden: Entsteht hier die nächste Milliardenstory?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3ES01 | ISIN: US15713L1098 | Ticker-Symbol: DP8
Tradegate
06.08.26 | 15:33
2,440 Euro
-1,61 % -0,040
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CERVOMED INC Chart 1 Jahr
5-Tage-Chart
CERVOMED INC 5-Tage-Chart
RealtimeGeldBriefZeit
2,4602,50007.08.
2,4402,52007.08.

Aktuelle News zur CERVOMED Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrCervoMed Inc. - S-8, Securities to be offered to employees in employee benefit plans1
DiCervoMed Inc. - 8-K, Current Report1
DiCervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)2
15.07.CervoMed: H.C. Wainwright bekräftigt "Buy"-Rating und Kursziel von 25 US-Dollar18
15.07.H.C. Wainwright reiterates CervoMed stock rating at buy, $25 target2
14.07.CervoMed presents dementia drug data at AAIC 2026 conference3
14.07.CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)3
09.07.CervoMed Inc. - 8-K, Current Report3
CERVOMED Aktie jetzt für 0€ handeln
09.07.H.C. Wainwright reiterates Buy on CervoMed stock, $25 target2
09.07.CervoMed completes enrollment in phase 2a nfvPPA trial1
09.07.CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia426Interim biomarker data accepted for presentation at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference Recent peer-reviewed data published in Nature Neuroscience demonstrate relevance...
► Artikel lesen
22.06.CervoMed closes $10 million registered direct offering3
22.06.CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules6
18.06.CervoMed prices $10M registered direct offering at $4/share2
18.06.CervoMed sichert sich 10 Mio. US-Dollar durch Direktplatzierung zu 4 US-Dollar je Aktie4
18.06.CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules2
18.06.CervoMed Stock Soars 61% After Patent Win For Dementia Drug Candidate3
18.06.CervoMed Inc. - 8-K, Current Report1
18.06.CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042283BOSTON, June 18, 2026 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today...
► Artikel lesen
12.06.CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit6
Weiter >>
48 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1